专利检索 ap:("Nicolas C. BOYER" OR "Michael B. GARRIGOU" OR "Sookhee Nicole HA" OR "Chunhui HUANG" OR "Anthony W. PARTRIDGE" OR "Tomi K. SAWYER" OR "Pietro ARONICA" OR "Charles W. JOHANNES" OR "Srinivasaraghavan KANNAN" OR "Chandra S. VERMA" OR "Tsz Ying YUEN" OR "Merck Sharp & Dohme LLC" OR "MSD International GMBH (Singapore Branch)" OR "Agency for Science, Technology AND Research") AND inv:"Chunhui Huang" 第 1 页

1.

发明申请
MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT 有权

公开(公告)号：US20230083431A1

公开(公告)日：2023-03-16

申请号：US17783224

申请日：2020-12-15

申请人： Nicolas C. BOYER , Michael B. GARRIGOU , Sookhee Nicole HA , Chunhui HUANG , Anthony W. PARTRIDGE , Tomi K. SAWYER , Pietro ARONICA , Charles W. JOHANNES , Srinivasaraghavan KANNAN , Chandra S. VERMA , Tsz Ying YUEN , Merck Sharp & Dohme LLC , MSD International GMBH (Singapore Branch) , Agency for Science, Technology and Research

发明人： Nicolas C. Boyer , Michael B. Garrigou , Sookhee Nicole Ha , Chunhui Huang , Anthony W. Partridge , Tomi K. Sawyer , Pietro Aronica , Charles W. Johannes , Srinivasaraghavan Kannan , Chandra S. Verma , Tsz Ying Yuen

IPC分类号： A61K38/12 , A61P35/00 , C07K7/52

摘要： The invention provides compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (K-Ras) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

2.

发明申请
INSULIN-INCRETIN CONJUGATES 审中-公开

公开(公告)号：US20190175744A1

公开(公告)日：2019-06-13

申请号：US16083201

申请日：2017-03-13

申请人： Anandan PALANI , Chunhui HUANG , Zhiqiang YANG , Lin YAN , Songnian LIN , Pei HUO , Qiaolin DENG , Elisabetta BIANCHI , Federica ORVIETO , Merck Sharp & Dohme Corp.

发明人： Anandan Palani , Chunhui Huang , Zhiqiang Yang , Lin Yan , Songnian Lin , Pei Huo , Qiaolin Deng , Elisabetta Bianchi , Federica Orvieto

IPC分类号： A61K47/64 , A61K38/28 , A61K38/26

摘要： Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.

3.

发明申请
PRMT5 INHIBITORS 有权

公开(公告)号：US20210309687A1

公开(公告)日：2021-10-07

申请号：US17266515

申请日：2019-08-05

申请人： Michelle MACHACEK , David WITTER , Chunhui HUANG , Shuhei KAWAMURA , Sebastian SCHNEIDER , Mrray WAN , Merck Sharp & Dohme Corp.

发明人： Michelle Machacek , David Witter , Chunhui Huang , Shuhei Kawamura , Sebastian Schneider , Murray Wan

IPC分类号： C07H19/14 , A61P35/00

摘要： The present invention provides a compound of formula (I) Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, are PRMT5 inhibitors. Also provided are methods of making compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.